Nektar sets quiet period before REZOLVE-AA data

Q: What did Nektar Therapeutics (NKTR) announce in this Form 8-K?

Nektar Therapeutics announced it is entering a quiet period beginning September 8, 2026, lasting until it publicly announces data from the 24-week off-treatment follow-up of its Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata.

Q: When does NKTR’s quiet period start and end?

The quiet period starts on September 8, 2026 and continues until the public announcement of data from the 24-week off-treatment follow-up period of the Phase 2b REZOLVE-AA study. No specific end date is given beyond that data announcement milestone.

Q: Which study is linked to the quiet period disclosed by NKTR?

The quiet period is linked to Nektar’s Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata, specifically covering the period until data from the 24-week off-treatment follow-up are publicly announced.

Available on EDGAR 09/08/2026 - 04:11 PM EDT Accepted by SEC EDGAR 09/08/2026 - 04:10 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Nektar Therapeutics (NKTR) announced that it is entering a quiet period starting September 8, 2026, which will continue until the public announcement of data from the 24-week off-treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.

The company states that this quiet period is consistent with its prior quiet periods for Phase 2b REZOLVE studies and planned data disclosures, and the information is furnished under Regulation FD rather than filed.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

quiet period, Regulation FD, Phase 2b REZOLVE-AA study, rezpegaldesleukin, +1 more

5 terms

quiet period regulatory

"is entering a quiet period beginning September 8, 2026 and continuing"

A quiet period is a short, temporary restriction on public communications by a company — and sometimes by analysts — around sensitive events such as an initial public offering or just before financial results. Think of it like a short news blackout that limits commentary so everyone bases decisions on the same official filings; for investors, it means less new information and potentially higher uncertainty or price swings until normal disclosure resumes.

Regulation FD regulatory

"Item 7.01 Regulation FD."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Phase 2b REZOLVE-AA study medical

"Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients"

rezpegaldesleukin medical

"REZOLVE-AA study of rezpegaldesleukin in patients"

alopecia areata medical

"in patients with severe-to-very-severe alopecia areata."

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, causing round patches of hair loss on the scalp or body; severity ranges from small spots to widespread baldness. Investors watch it because successful treatments, clinical trial results, regulatory approvals, or shifts in prevalence can create or shrink markets for drugs and therapies, affecting the value of companies developing remedies—think of it as demand risk and regulatory risk for hair-loss products.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nektar Therapeutics (NKTR) announce in this Form 8-K?

Nektar Therapeutics announced it is entering a quiet period beginning September 8, 2026, lasting until it publicly announces data from the 24-week off-treatment follow-up of its Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata.

When does NKTR’s quiet period start and end?

The quiet period starts on September 8, 2026 and continues until the public announcement of data from the 24-week off-treatment follow-up period of the Phase 2b REZOLVE-AA study. No specific end date is given beyond that data announcement milestone.

Which study is linked to the quiet period disclosed by NKTR?

The quiet period is linked to Nektar’s Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata, specifically covering the period until data from the 24-week off-treatment follow-up are publicly announced.

Is the information in NKTR’s 8-K considered filed or furnished?

The company states the information under Item 7.01 is being furnished, not “filed,” under the Exchange Act. It is not subject to Section 18 liabilities and will not be incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

Is this quiet period consistent with Nektar Therapeutics’ past practice?

Yes. Nektar notes that implementation of this quiet period is consistent with its prior quiet periods related to the Phase 2b REZOLVE studies and its planned data disclosures, indicating this is a recurring practice around such data events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 8, 2026

NEKTAR THERAPEUTICS

(Exact Name of Registrant as Specified in Charter)

Delaware		0-24006		94-3134940
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

455 Mission Bay Boulevard South

San Francisco, California 94158

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (415) 482-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		NKTR		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD.

Nektar Therapeutics (the “Company”) is entering a quiet period beginning September 8, 2026 and continuing until the public announcement of data from the 24-week off treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata. The implementation of the quiet period is consistent with the Company’s prior quiet periods pertaining to the Phase 2b REZOLVE studies and planned data disclosures.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEKTAR THERAPEUTICS

Date: September 8, 2026	By:	/s/ Elizabeth Zhang
		Elizabeth Zhang
		Vice President, Legal

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents